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Another treatment option for relapsed or refractory chronic 
lymphocytic leukaemia 
Most patients with chronic lymphocytic leukaemia 
relapse after front-line chemoimmunotherapy and 
a substantial proportion develop adverse genetic 
abnormalities leading to disease that is refractory to 
treatment. The introduction of targeted agents, such 
as the kinase inhibitors ibrutinib and idelalisib and the 
BCL2 antagonist venetoclax, has substantially improved 
the outcomes of patients with relapsed or refractory 
chronic lymphocytic leukaemia.1–3 These agents induce 
durable responses in patients with standard as well as 
high-risk disease features.4–6
In The Lancet Oncology, Andrew Zelenetz and 
colleagues7 report the interim results of a phase 3 
randomised controlled trial investigating whether 
the effectiveness of salvage treatment with the 
combination of bendamustine and rituximab, a widely 
used chemoimmunotherapy regimen in patients 
with relapsed or refractory chronic lymphocytic 
leukaemia,8 could be improved by the addition of 
idelalisib—a first-in-class phosphoinositide-3-kinase 
δ inhibitor. The primary endpoint of this study was 
progression-free survival. All patients received up to 
six cycles of bendamustine plus rituximab and were 
randomly assigned to receive twice-daily oral idelalisib 
or matching placebo, administered continuously 
until disease progression or unacceptable toxicity. 
The median age of the patients was 63 years, and the 
median number of previous treatment regimens was 
two. Most of the 416 enrolled patients (346 [83%]) 
had unmutated IGHV and about a third had either 
del(17p) or TP53 mutation.
Patients who received idelalisib in addition to 
bendamustine plus rituximab had significantly better 
outcomes compared with those assigned to placebo in 
terms of the proportion achieving an overall response 
(70% [145/207] in the idelalisib group vs 45% 
[94/209] in the placebo group), median progression-
free survival (20·8 months vs 11·1 months), and 
median overall survival (not reached vs 31·6 months). 
The benefit of idelalisib was consistent across most 
prespecified high-risk subgroups. Median progression-
free survival in patients in the idelalisib group 
compares favourably to that in patients with relapsed 
or refractory chronic lymphocytic leukaemia treated 
with bendamustine plus rituximab in the study by 
Fischer and colleagues (15·2 months).8 It should 
be noted that median progression-free survival in 
patients with neither del(17p) nor TP53 mutation 
who received idelalisib in addition to bendamustine 
plus rituximab was 24·5 months, whereas it was not 
reached with ibrutinib combined with bendamustine 
and rituximab in the HELIOS trial, which excluded 
patients with del(17p).9 Additionally, in Zelenetz 
and colleagues’ study, idelalisib was associated with 
significant clinical activity in patients with either 
del(17p) or TP53 mutation, a subset of patients who 
are resistant to chemotherapy. Findings from studies 
with other targeted agents show also long response 
durations in these patients.7,8 
However, the contribution of bendamustine to the 
effects of this treatment regimen is unclear, since 
median progression-free survival in patients assigned 
to idelalisib combined with bendamustine and 
rituximab (20·8 months) is similar to that previously 
reported in frail patients treated with idelalisib 
combined with rituximab (19·4 months).3 Similarly, 
no differences in progression-free or overall survival 
were reported in patients who received ibrutinib as 
a single agent or combined with bendamustine and 
rituximab in a study that combined data from two 
phase 3 trials in patients with relapsed or refractory 
chronic lymphocytic leukaemia.10 Because the addition 
of chemoimmunotherapy can potentially increase 
the risk of infection, this issue might be worth 
investigating.
Moreover, treatment-related toxicity was not a 
negligible issue in this study. The proportion of patients 
receiving idelalisib who discontinued treatment because 
of an adverse event was 28%—twice as high as the 
proportion in the placebo group. Infections, mostly 
bacterial, were more common and were more frequently 
responsible for treatment discontinuation or death 
in patients in the idelalisib group than in the placebo 
group. Additionally, the opportunistic infections 
Pneumocystis jirovecii and cytomegalovirus were more 
frequent in patients treated with idelalisib than in those 
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Bladder urothelial carcinoma can be a devastating 
disease and has profound personal and socioeconomic 
impact. It is the fifth most commonly diagnosed 
cancer in the USA: nearly 77 000 people were newly 
diagnosed in 2016, and more than 16 000 individuals 
died.1 Bladder urothelial carcinoma also has a high 
prevalence (over 450 000 in the USA) and tends to 
recur (in 50–80% of cases depending on disease stage), 
necessitating intense life-long surveillance. Urothelial 
carcinoma is, in most high-income countries, one of 
the most expensive cancers to treat on a per-patient 
basis.2 Fortuitously, after decades of inertia because 
of an almost complete lack of awareness and interest, 
progress in immune oncology is awakening new hopes 
and opportunities.
Immune checkpoint inhibitors promise to transform 
the seemingly unmovable prognosis of patients 
with metastatic urothelial carcinoma. In 1990, the 
US Food and Drug Administration approved the 
first indication for an immunotherapeutic drug—
who received placebo. However, it should be noted 
that patients in the idelalisib group continued therapy 
indefinitely and that prophylaxis for P jirovecii and 
monitoring for cytomegalovirus were not mandatory in 
this study.
The increased rate of infections recorded this study 
is similar to that reported in three other studies 
investigating idelalisib combined with bendamustine 
and rituximab for the first-line treatment of chronic 
lymphocytic leukaemia or for the treatment of relapsed 
indolent non-Hodgkin lymphoma, and idelalisib in 
combination with rituximab in patients with relapsed 
indolent non-Hodgkin lymphoma. The currently 
recommended measures to prevent and monitor 
infections, cytomegalovirus monitoring, P jirovecii 
prophylaxis, and regular blood tests for granulocyte 
counts in patients receiving idelalisib,  are expected 
to have a positive effect in reducing the number of 
infections. 
During the past few years, with the introduction of 
targeted agents, the treatment landscape of chronic 
lymphocytic leukaemia has evolved rapidly, with 
favourable consequences for patient outcomes. 
This study shows that the addition of idelalisib to 
bendamustine and rituximab can significantly improve 
outcomes of patients with relapsed or refractory 
chronic lymphocytic leukaemia compared with 
bendamustine plus rituximab alone. However, further 
studies are needed to define the benefit of combining 
chemoimmunotherapy with kinase inhibitors. Careful 
selection of patients, better knowledge, management 
of treatment-related adverse events, and enforcement 
measures to mitigate the risk of infections might have 
relevant effects in maximising the therapeutic benefit 
of idelalisib.
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